Table I.
Distribution of voriconazole and voriconazole N-oxide into interstitial space fluid (ISF) of four healthy individuals assessed as ratios of area under the concentration time curve (AUC) in ISF to plasma in the three dosing intervals with intensive sampling
| CYP2C19 metabolizer | AUCISF/AUCPlasma | ||
|---|---|---|---|
| Dosing interval | |||
| 1 | 5 | 7 | |
| Voriconazole | |||
| Rapid metabolizer | 0.440 | 0.682 | 0.624 |
| Normal metabolizer | 0.425 | 0.620 | 0.601 |
| Rapid/poor metabolizer | 0.506 | 0.464 | 0.524 |
| Intermediate metabolizer | 0.355 | 0.698 | 0.564 |
| Voriconazole N-oxide | |||
| Rapid metabolizer | 0.245 | 0.262 | 0.329 |
| Normal metabolizer | 0.242 | 0.443 | 0.494 |
| Rapid/poor metabolizer | 0.243 | 0.270 | 0.397 |
| Intermediate metabolizer | 0.0564 | 0.0683 | 0.0769 |